[go: up one dir, main page]

MX2010008994A - Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario. - Google Patents

Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.

Info

Publication number
MX2010008994A
MX2010008994A MX2010008994A MX2010008994A MX2010008994A MX 2010008994 A MX2010008994 A MX 2010008994A MX 2010008994 A MX2010008994 A MX 2010008994A MX 2010008994 A MX2010008994 A MX 2010008994A MX 2010008994 A MX2010008994 A MX 2010008994A
Authority
MX
Mexico
Prior art keywords
combination
paclitaxel
ovarian cancer
treating ovarian
treating
Prior art date
Application number
MX2010008994A
Other languages
English (en)
Inventor
Martine Clozel
Urs Regenass
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40670930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010008994(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2010008994A publication Critical patent/MX2010008994A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a la combinación de un antagonista del receptor de la endotelina de fórmula (I) con paclitaxel, y, en particular a esta combinación para su uso terapéutico, simultáneamente, por separado o en un período de tiempo, en el tratamiento del cáncer de ovario.
MX2010008994A 2008-02-20 2009-02-19 Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario. MX2010008994A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008050607 2008-02-20
PCT/IB2009/050677 WO2009104149A1 (en) 2008-02-20 2009-02-19 Combination comprising paclitaxel for treating ovarian cancer

Publications (1)

Publication Number Publication Date
MX2010008994A true MX2010008994A (es) 2010-09-07

Family

ID=40670930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008994A MX2010008994A (es) 2008-02-20 2009-02-19 Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.

Country Status (19)

Country Link
US (2) US8541433B2 (es)
EP (1) EP2254570B1 (es)
JP (1) JP5514123B2 (es)
KR (1) KR20100132489A (es)
CN (1) CN101939001B (es)
AR (1) AR070456A1 (es)
AU (1) AU2009215329B2 (es)
CA (1) CA2714608A1 (es)
CY (1) CY1115071T1 (es)
DK (1) DK2254570T3 (es)
ES (1) ES2446303T3 (es)
HR (1) HRP20140215T1 (es)
MX (1) MX2010008994A (es)
PL (1) PL2254570T3 (es)
PT (1) PT2254570E (es)
RU (1) RU2494736C2 (es)
SI (1) SI2254570T1 (es)
TW (1) TWI441639B (es)
WO (1) WO2009104149A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292209A3 (en) 2005-09-12 2011-05-04 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyramidine-sulfamide
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
PT2254570E (pt) * 2008-02-20 2014-02-17 Actelion Pharmaceuticals Ltd Combinação que compreende paclitaxel para o tratamento de cancro de ovário
KR101678699B1 (ko) 2008-08-13 2016-11-23 액테리온 파마슈티칼 리미티드 마시텐탄을 포함하는 치료 조성물
PT2464218E (pt) 2009-08-10 2015-09-16 Univ Texas Tratamento de metástases do cérebro com inibidores de recetores de endotelina, em combinação com um agente quimioterapêutico citotóxico
BR112013019680A2 (pt) * 2011-02-04 2016-10-11 Actelion Pharmaceuticals Ltd combinações compreendendo macitentana para o tratamento de glioblastoma multiforme
CN103819411A (zh) * 2014-03-14 2014-05-28 成都克莱蒙医药科技有限公司 一种马西替坦中间体新的制备方法
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
ATE323079T1 (de) * 2000-12-18 2006-04-15 Actelion Pharmaceuticals Ltd Neue sulfamiden und deren verwendung als endothelin-antagonisten
CA2502848C (en) 2002-10-24 2012-10-02 The Board Of Trustees Of The University Of Illinois Use of irl-1620 and paclitaxel for preventing and treating breast tumors
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
EP2292209A3 (en) 2005-09-12 2011-05-04 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyramidine-sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
PT2254570E (pt) * 2008-02-20 2014-02-17 Actelion Pharmaceuticals Ltd Combinação que compreende paclitaxel para o tratamento de cancro de ovário
KR20100005486A (ko) * 2008-07-07 2010-01-15 페어차일드코리아반도체 주식회사 스위치 제어 장치 및 이를 포함하는 컨버터

Also Published As

Publication number Publication date
DK2254570T3 (da) 2014-02-03
TWI441639B (zh) 2014-06-21
ES2446303T3 (es) 2014-03-07
AU2009215329B2 (en) 2014-08-21
KR20100132489A (ko) 2010-12-17
EP2254570B1 (en) 2013-12-18
SI2254570T1 (sl) 2014-03-31
JP5514123B2 (ja) 2014-06-04
PL2254570T3 (pl) 2014-05-30
CY1115071T1 (el) 2016-12-14
HRP20140215T1 (hr) 2014-04-11
WO2009104149A1 (en) 2009-08-27
US20130317048A1 (en) 2013-11-28
TW200940062A (en) 2009-10-01
EP2254570A1 (en) 2010-12-01
RU2494736C2 (ru) 2013-10-10
CN101939001B (zh) 2012-06-20
US20100311774A1 (en) 2010-12-09
RU2010138650A (ru) 2012-03-27
PT2254570E (pt) 2014-02-17
AR070456A1 (es) 2010-04-07
JP2011512399A (ja) 2011-04-21
AU2009215329A1 (en) 2009-08-27
CA2714608A1 (en) 2009-08-27
CN101939001A (zh) 2011-01-05
US8541433B2 (en) 2013-09-24

Similar Documents

Publication Publication Date Title
EA201171367A1 (ru) Винилиндазолильные соединения
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
UA107782C2 (ru) Антагонисты рецепторов fgf-r4
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2019015200A (es) Compuestos de diarilhidantoina.
CR10995A (es) Inhibidores de la actividad de akt
ZA201201984B (en) Treating notch1- antagonist- resistant cancer (s)using notch3 antagonists
IN2012DN00971A (es)
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
MY150600A (en) Use of opioid antagonists for treating urinary retention
PH12015501088A1 (en) Dimeric compounds
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
IL202001A0 (en) Axomadol for treating pain from arthritis
MX2010009697A (es) Tratamientos anticancerigenos mejorados.
MX2009007054A (es) Uso terapeutico novedoso para tratar leucemia.
MX2011006532A (es) Compuestos anticancerigenos.
ZA200705490B (en) Substituted benzimidazoles for treatment of histomoniasis
TN2012000552A1 (en) An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative

Legal Events

Date Code Title Description
FG Grant or registration